[A22-114] Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V
Last updated 06.04.2023
Project no.:
A22-114
Commission:
Commission awarded on 18.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy
hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-12 | Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114 | Commission completed |
Federal Joint Committee (G-BA)
2023-04-06 A G-BA decision was published.